Current Report Filing (8-k)
March 16 2022 - 8:31AM
Edgar (US Regulatory)
0001633070
false
0001633070
2022-03-16
2022-03-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 16, 2022
AXCELLA
HEALTH INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38901 |
|
26-3321056 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
840
Memorial Drive
Cambridge,
Massachusetts |
02139 |
(Address
of principal executive offices) |
(Zip
Code) |
Registrant's telephone number, including area
code (857) 320-2200
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of
each class |
|
Trading
symbol(s) |
|
Name of each
exchange
on which registered |
Common
Stock, $0.001 par value |
|
AXLA |
|
Nasdaq
Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 |
Entry into a Material Definitive Agreement. |
On March 16, 2022, Axcella Health Inc. (the
“Company” or “Axcella”), doing business as “Axcella Therapeutics”, entered into a Securities
Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”). Pursuant
to the Purchase Agreement, the Company agreed to issue and sell in a registered direct offering an aggregate of 13,089,002 shares of
the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.91 per
share (the “Offering”). The net proceeds to the Company are expected to be approximately $24.9 million after
deducting estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the Offering to
complete its Long COVID Phase 2a clinical trial and, assuming positive data, its regulatory dialogue regarding next steps for this
program; complete enrollment of its EMMPACT Phase 2b clinical trial in non-alcoholic steatohepatitis (NASH); advance its EMMPOWER
Phase 2 clinical trial in OHE; and for working capital and other general corporate purposes. The Offering is anticipated to close on
or about March 16, 2022.
The Purchase Agreement contains customary representations, warranties,
and agreements by the Company, and customary indemnification and other obligations of the Company and the Purchasers. Pursuant to the
terms of the Purchase Agreement, the Company has also agreed to certain restrictions on the issuance and sale of its securities until
60 days following the date of the Purchase Agreement, subject to certain exceptions. Also, pursuant to the terms of the Purchase Agreement,
the Purchasers have certain rights to participate in subsequent issuances of the Company’s securities during the 6 month period
following the date of the Purchase Agreement, subject to certain exceptions.
The shares of Common Stock will be offered and sold by the Company
pursuant to an effective shelf registration statement on Form S-3 (File No. 333-238983), which was originally filed with the
Securities and Exchange Commission on June 5, 2020, and was declared effective on June 12, 2020 (the “Registration Statement”).
The foregoing summary of the Purchase Agreement is qualified in its
entirety by the full text of the Purchase Agreement, the form of which is filed herewith as Exhibit 10.1 and incorporated herein
by reference. The form of Purchase Agreement is attached hereto as an exhibit to provide investors and security holders with information
regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and
covenants contained in the Purchase Agreement were made only for purposes of the Purchase Agreement and as of specific dates, were solely
for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties.
A copy of the legal opinion of Goodwin Procter LLP, relating to the
validity of the shares issued in the Offering, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is filed with
reference to, and is hereby incorporated by reference into, the Registration Statement.
On March 16, 2022, the Company issued a press release announcing
the Offering, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AXCELLA HEALTH INC. |
|
|
Date: March 16, 2022 |
By: |
/s/ William R. Hinshaw, Jr. |
|
|
William R. Hinshaw, Jr. |
|
|
President, Chief Executive Officer and Director |
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Jul 2023 to Jul 2024